D. Arnold

D. Arnold, L. Gavin, J. Barth, 2000, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Early neuroaxonal injury is seen in the acute phase of pediatric optic neuritis.

D. Arnold, A. Bar-Or, A. Wong, 2019, Multiple sclerosis and related disorders.

Metabolic Changes in Cerebral Gliomas Within Hours of Treatment With Intra-Arterial BCNU Demonstrated by Phosphorus Magnetic Resonance Spectroscopy

E. Shoubridge, D. Arnold, J. Villemure, 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Fitting cytosolic ADP recovery after exercise with a step response function

R. Kearney, D. Arnold, Z. Argov, 1999, Magnetic resonance in medicine.

ADP Recovery After a Brief Ischemic Exercise in Normal and Diseased Human Muscle — a 31P MRS Study

D. Arnold, Z. Argov, N. de Stefano, 1996, NMR in biomedicine.

MR spectroscopy and imaging in metabolic myopathies.

D. Arnold, Z. Argov, 2000, Neurologic clinics.

Ca2+-ATPase deficiency in a patient with an exertional muscle pain syndrome.

D. Arnold, G. Radda, P. Styles, 1988, Journal of neurology, neurosurgery, and psychiatry.

R E V I E W A R T I C L E 1 H-MRS quantiﬁcation of tNA and tCr in patients with multiple sclerosis: a meta-analytic review

D. Arnold, Z. Caramanos, S. Narayanan, 2005 .

Association of cerebral dysgenesis and lactic acidemia with X-linked PDH E1 alpha subunit mutations in females.

P. Matthews, D. Arnold, G. Brown, 1995, Pediatric neurology.

Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study

D. Arnold, L. Kappos, P. Vermersch, 2022, Journal of Neurology.

Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial

D. Arnold, L. Kappos, P. Vermersch, 2022, Multiple sclerosis.

Improving the SIENA performance using BEaST brain extraction

Alzheimer's Disease Neuroimaging Initiative, D. Arnold, S. Eskildsen, 2018, PloS one.

Permanent tissue damage in multiple sclerosis lesions is associated with reduced pre-lesion myelin and axon volume fractions

G. B. Pike, D. Arnold, D. Rudko, 2022, Multiple sclerosis.

Incidence of acquired demyelination of the CNS in Canadian children

D. Arnold, A. Bar-Or, B. Banwell, 2009, Neurology.

A mitochondrial encephalomyopathy A combined 31P magnetic resonance and biochemical investigation

D. J. Hayes, D. Arnold, G. Radda, 1985, Journal of the Neurological Sciences.

Short‐term aerobic training response in chronic myopathies

D. Arnold, T. Taivassalo, Z. Argov, 1999, Muscle & nerve.

ESTIMATING AND ACCOUNTING FOR THE EFFECT OF MRI SCANNER HARDWARE CHANGES ON LONGITUDINAL WHOLE-BRAIN ATROPHY MEASUREMENTS

D. Arnold, Kunio Nakamura, S. Narayanan, 2016, Alzheimer's & Dementia.

Muscle phosphorus magnetic resonance spectroscopy oxidative indices correlate with physical activity

D. Arnold, Z. Caramanos, T. Taivassalo, 2000, Muscle & nerve.

Evidence for mitochondrial dysfunction in patients with alternating hemiplegia of childhood

D. Arnold, F. Andermann, K. Silver, 1993, Annals of neurology.

INDICES CORRELATE WITH PHYSICAL ACTIVITY

D. Arnold, Z. Caramanos, M. Tartaglia, 2022 .

How patients with multiple sclerosis acquire disability

Thomas E. Nichols, D. Arnold, H. Ganjgahi, 2022, Brain : a journal of neurology.

Imaging of axonal damage in vivo in Rasmussen's syndrome.

D. Arnold, F. Cendes, F. Andermann, 1995, Brain : a journal of neurology.

Secondary Progressive Multiple Sclerosis New Insights

D. Arnold, T. Chitnis, R. Fox, 2021 .

Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis

D. Arnold, B. Kieseier, S. Newsome, 2016, Journal of Neurology.

Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo

D. Arnold, E. Pioro, N. Cashman, 1994, Neurology.

Unusual Imaging Findings in Progressive Myoclonus Epilepsy

E. Shoubridge, D. Arnold, F. Andermann, 2001, Epilepsia.

P 1 Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis – analysis of the phase III, double-blind, double-dummy, interferon beta-1a- controlled OPERA I and OPERA II studies

G. Comi, D. Arnold, A. Bar-Or, 2017, Clinical Neurophysiology.

Phosphorus magnetic resonance spectroscopy of brain in mitochondrial cytopathies

P. Matthews, D. Arnold, P. Matthews, 1990, Annals of neurology.

Investigation of human mitochondrial myopathies by phosphorus magnetic resonance spectroscopy.

D. Arnold, G. Radda, D. Taylor, 1985, Biochemical Society transactions.

Diurnal fluctuations in brain volume: Statistical analyses of MRI from large populations

D. Louis Collins, Kunio Nakamura, Douglas L. Arnold, 2015, NeuroImage.

Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability.

Antonio Federico, Sridar Narayanan, Douglas L Arnold, 2002, Archives of neurology.

The use of magnetic resonance spectroscopy in the evaluation of the natural history of multiple sclerosis.

P. Matthews, D. Arnold, A. Falini, 1998, Journal of neurology, neurosurgery, and psychiatry.

Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years

D. Arnold, L. Kappos, P. Vermersch, 2022, Multiple sclerosis.

A proton magnetic resonance spectroscopy study of focal epilepsy in humans

P. Matthews, D. Arnold, F. Andermann, 1990, Neurology.

Axonal pathology in patients with multiple sclerosis: evidence from in vivo proton magnetic resonance spectroscopy

P. Matthews, D. Arnold, Zografos Caramos, 2007 .

Magnetization transfer ratio recovery in new lesions decreases during adolescence in pediatric-onset multiple sclerosis patients

Douglas L. Arnold, Sridar Narayanan, D. Arnold, 2014, NeuroImage: Clinical.

Normalization of Magnetization Transfer Ratio MRI For Multicentre Clinical Trials

R. A. Brown, D. Arnold, H. Atkins, 2010 .

Early Metabolic Changes Following Chemotherapy of Human Gliomas In Vivo Demonstrated by Phosphorus Magnetic Resonance Spectroscopy

E. Shoubridge, D. Arnold, J. Villemure, 1989, Investigative radiology.

Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy.

P M Matthews, P. Matthews, D. Arnold, 1996, Brain : a journal of neurology.

Proton and phosphorus magnetic resonance spectroscopy of human astrocytomas in vivo. Preliminary observations on tumor grading

E. Shoubridge, D. Arnold, J. Villemure, 1990, NMR in biomedicine.

MRI correlates of cognitive impairment in childhood-onset multiple sclerosis.

D. Collins, D. Arnold, J. Sled, 2011, Neuropsychology.

Lateralization of temporal lobe epilepsy based on regional metabolic abnormalities in proton magnetic resonance spectroscopic images

D. Arnold, F. Cendes, F. Andermann, 1994, Annals of neurology.

Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria

D. Arnold, A. Bar-Or, B. Banwell, 2022, Multiple sclerosis.

Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial

D. Arnold, S. Reingold, C. Pozzilli, 2020, The Lancet Neurology.

MR image-guided P-31 MR spectroscopy in the evaluation of brain tumor treatment.

D. Arnold, C. Segebarth, D. Baleriaux, 1987, Radiology.

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

Jeffrey A. Cohen, Islam M. Zaydan, Gregory F. Wu, 2022, The Lancet Neurology.

Efficacy and safety of ocrelizumab in relapsing multiple sclerosis: Results of the IFN-β-1a-controlled, double-blind, Phase III OPERA I and II studies

D. Arnold, L. Kappos, A. Bar-Or, 2016 .

Present and future of the diagnostic work-up of multiple sclerosis: the imaging perspective

D. Arnold, F. Barkhof, X. Montalban, 2022, Journal of Neurology.

Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study

D. Arnold, X. Montalban, A. Bar-Or, 2015 .

Single-timepoint Low-dimensional Characterization and Classification of Acute versus Chronic Multiple Sclerosis Lesions using Machine Learning

N. Paragios, D. Arnold, E. Fisher, 2022, NeuroImage.

Robust automatic segmentation of hippocampus from multisite MRI data

D. Louis Collins, Tao Li, Douglas L. Arnold, 2009, Alzheimer's & Dementia.

No-reference quality measure in brain MRI images using binary operations, texture and set analysis

Douglas L. Arnold, Marius Pedersen, Katrina Wendel-Mitoraj, 2017, IET Image Process..

Magnetic resonance spectroscopy of multiple sclerosis: imaging axonal damage

Paul M. Matthews, Douglas L. Arnold, Nicola De Stefano, 2001 .

Impairment of muscle mitochondrial oxidative metabolism in McArdle's disease

P. Matthews, D. Arnold, Z. Argov, 1996, Muscle & nerve.

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial

Jeffrey A. Cohen, D. Arnold, X. Montalban, 2022, Multiple sclerosis.

Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program.

Jeffrey A. Cohen, D. Arnold, X. Montalban, 2021, Multiple sclerosis and related disorders.

Intracellular phosphates in inclusion body myositis--a 31P magnetic resonance spectroscopy study.

D. Arnold, T. Taivassalo, A. Genge, 1998, Muscle & nerve.

Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN

D. Arnold, G. Nelles, M. Kremenchutzky, 2018, Therapeutic advances in neurological disorders.

Brain phosphorus magnetic resonance spectroscopy in acute bacterial meningitis.

P. Matthews, E. Shoubridge, D. Arnold, 1989, Archives of Neurology.

Simulation-based power analysis could improve the design of clinical trials in Alzheimer's disease

D. Arnold, H. Chertkow, D. L. Collins, 2022, medRxiv.

Magnetic Resonance Spectroscopy in Niemann-Pick Type C: Corrdation With Di is Clinical Response to Ch styramine and Lovas tin

D. Arnold, M. Shevell, R. Schreiber, 1994 .

Single-timepoint low-dimensional characterization and classification of acute versus chronic multiple sclerosis lesions using machine learning

N. Paragios, D. Arnold, E. Fisher, 2022, NeuroImage.

Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression?

D. Arnold, A. Bar-Or, J. Oger, 2009, Multiple sclerosis.

Altered resting-state functional connectivity in cognitively preserved pediatric-onset MS patients and relationship to structural damage and cognitive performance

Sridar Narayanan, Berengere Aubert-Broche, Malcolm A Binns, 2016, Multiple sclerosis.

Estimating and accounting for the effect of MRI scanner changes on longitudinal whole-brain volume change measurements

Hyunwoo Lee, Kunio Nakamura, Douglas L. Arnold, 2019, NeuroImage.

Magnetic resonance techniques for the in vivo assessment of multiple sclerosis pathology: Consensus report of the white matter study group

D. Arnold, M. Filippi, A. Falini, 2005, Journal of magnetic resonance imaging : JMRI.

Magnetic Resonance Imaging and Spectroscopy : Insights into the Pathology and Pathophysiology of Multiple Sclerosis .

D. Arnold, Z. Caramanos, A. C. Santos, 2002 .

Chemical pathology of acute demyelinating lesions and its correlation with disability

P. Matthews, D. Arnold, J. Antel, 1995, Annals of neurology.

Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis

P. Matthews, D. Arnold, C. Wolfson, 1994, Annals of neurology.

The metabolic potential of the paediatric-onset multiple sclerosis gut microbiome.

D. Arnold, A. Bar-Or, Yinshan Zhao, 2022, Multiple sclerosis and related disorders.

Path Sampling to Compute Integrated Likelihoods: An Adaptive Approach

Geneviève Lefebvre, Douglas L. Arnold, Russell Steele, 2009 .

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.

D. Arnold, G. Kraft, J. Bowen, 2015, JAMA neurology.

Deep grey matter injury in multiple sclerosis: A NAIMS consensus statement.

D. Greve, D. Arnold, D. Reich, 2021, Brain : a journal of neurology.

MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis

D. Arnold, Kunio Nakamura, J. Maranzano, 2017, Neurology.

Review of automatic segmentation methods of multiple sclerosis white matter lesions on conventional magnetic resonance imaging

D. Louis Collins, Douglas L. Arnold, Simon J. Francis, 2013, Medical Image Anal..

Optimizing Operating Points for High Performance Lesion Detection and Segmentation Using Lesion Size Reweighting pdf

Tal Arbel, Douglas L. Arnold, Brennan Nichyporuk, 2021, ArXiv.

Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data

D. Arnold, O. Ciccarelli, A. Thompson, 2021, Nature Communications.

Brain volume loss in individuals over time: Source of variance and limits of detectability

D. Louis Collins, Vladimir Fonov, Kunio Nakamura, 2020, NeuroImage.

Temporally Consistent Probabilistic Detection of New Multiple Sclerosis Lesions in Brain MRI

D. Louis Collins, Tal Arbel, Douglas L. Arnold, 2013, IEEE Transactions on Medical Imaging.

Evaluating intensity normalization on MRIs of human brain with multiple sclerosis

D. Louis Collins, Mohak Shah, Tal Arbel, 2011, Medical Image Anal..

Standardized quality metric system for structural brain magnetic resonance images in multi-center neuroimaging study

Marius Pedersen, Douglas L. Arnold, Michael E. Osadebey, 2018, BMC Medical Imaging.

Bayesian framework inspired no-reference region-of-interest quality measure for brain MRI images

Marius Pedersen, Katrina Wendel-Mitoraj, Michael Osadebey, 2017, Journal of medical imaging.

Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations

Douglas L Arnold, Yves Lapierre, D. Arnold, 2013, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Detection of Gad-Enhancing Lesions in Multiple Sclerosis Using Conditional Random Fields

D. Louis Collins, Mohak Shah, Tal Arbel, 2010, MICCAI.

Glutaric acidemia type II: neuroimaging and spectroscopy evidence for developmental encephalomyopathy.

D. Arnold, M. Shevell, C. Scriver, 1995, Pediatric neurology.

Predicting surgical outcome in temporal lobe epilepsy patients using MRI and MRSI

R E Kearney, F Cendes, R. Shinghal, 2002, Neurology.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Jeffrey A. Cohen, D. Arnold, H. Hartung, 2012, The Lancet.

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Christian Confavreux, Gavin Giovannoni, Elizabeth Fisher, 2012, The Lancet.

Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosis

D. Arnold, A. Bar-Or, B. Banwell, 2019, Brain : a journal of neurology.

Insights into muscle diseases gained by phosphorus magnetic resonance spectroscopy

D. Arnold, D L Arnold, Z Argov, 2000, Muscle & nerve.

Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy.

D. Arnold, J. Villemure, Z. Caramanos, 2000, Neurosurgery.

Heterogeneity of T‐lymphocyte function in primary progressive multiple sclerosis: Relation to magnetic resonance imaging lesion volume

D. Arnold, D. Pelletier, J. Antel, 2000, Annals of neurology.

Predicting personalised risk of disability worsening in multiple sclerosis with machine learning

D. Arnold, O. Ciccarelli, A. Thompson, 2022, medRxiv.

Metagenomic Analysis of the Pediatric-Onset Multiple Sclerosis Gut Microbiome

D. Arnold, A. Bar-Or, Yinshan Zhao, 2021, Neurology.

Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes

D. Arnold, O. Ciccarelli, F. Barkhof, 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring

D. Arnold, P. Calabresi, R. Rudick, 2020, Multiple sclerosis.

A surface‐in gradient of thalamic damage evolves in pediatric multiple sclerosis

Douglas L. Arnold, Ruth Ann Marrie, Russell T. Shinohara, 2019, Annals of neurology.

Alemtuzumab CARE-MS II 5-year follow-up

Jeffrey A. Cohen, D. Arnold, H. Hartung, 2017, Neurology.

Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?

D. Arnold, Z. Caramanos, T. Kuhlmann, 2012, Acta Neuropathologica.

Large, nonplateauing relationship between clinical disability and cerebral white matter lesion load in patients with multiple sclerosis.

Zografos Caramanos, Sridar Narayanan, Yves Lapierre, 2012, Archives of neurology.

1 H-MRS quantification of tNA and tCr in patients with multiple sclerosis : a meta-analytic review

D. Arnold, Z. Caramanos, S. Narayanan, 2005 .

Proton MR spectroscopy to assess axonal damage in multiple sclerosis and other white matter disorders.

P. Matthews, D. Arnold, S. Narayanan, 2000, Journal of neurovirology.

Combined magnetization transfer and proton spectroscopic imaging in the assessment of pathologic brain lesions in multiple sclerosis.

G S Francis, G B Pike, G. B. Pike, 1999, AJNR. American journal of neuroradiology.

Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.

D. Arnold, X. Montalban, J. Wolinsky, 2019, The New England journal of medicine.

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

Bernhard Hemmer, Ludwig Kappos, Stephen L. Hauser, 2017, The New England journal of medicine.

Using Deep Learning Algorithms to Automatically Identify the Brain MRI Contrast: Implications for Managing Large Databases

Dante De Nigris, D. Arnold, A. Shmuel, 2018, Neuroinformatics.

2010 McDonald criteria for diagnosing pediatric multiple sclerosis

D. Arnold, A. Bar-Or, J. Sled, 2012, Annals of neurology.

MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study

D. Arnold, A. Bar-Or, J. Sled, 2011, The Lancet Neurology.

Delineation of cortical pathology in multiple sclerosis using multi-surface magnetization transfer ratio imaging

Douglas L. Arnold, Sridar Narayanan, Mishkin Derakhshan, 2016, NeuroImage: Clinical.

Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial

D. Arnold, P. Calabresi, A. Bar-Or, 2008, Annals of neurology.

Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study.

P M Matthews, G S Francis, P. Matthews, 1998, Brain : a journal of neurology.

Robust Rician noise estimation for MR images

D. Louis Collins, Pierrick Coupé, José V. Manjón, 2010, Medical Image Anal..

Effects of aerobic training in patients with mitochondrial myopathies

P. Matthews, D. Arnold, T. Taivassalo, 1998, Neurology.

Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

D. Arnold, P. Calabresi, L. Balcer, 2014, The Lancet Neurology.

Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study

D. Arnold, L. Kappos, A. Bar-Or, 2014, Journal of Neurology.

Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination

D. Arnold, A. Bar-Or, B. Banwell, 2016, Multiple sclerosis.

Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.

D. Arnold, L. Weiner, A. Bar-Or, 2007, Archives of neurology.

High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS

D. Arnold, G. Kraft, J. Bowen, 2017, Neurology.

Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial

D. Arnold, H. Atkins, A. Bar-Or, 2016, The Lancet.

Fatigue in Post‐poliomyelitis Syndrome: Association With Disease‐Related, Behavioral, and Psychosocial Factors

D. Arnold, A. Bar-Or, Z. Caramanos, 2009, PM & R : the journal of injury, function, and rehabilitation.

Gabapentin therapy for amyotrophic lateral sclerosis: lack of improvement in neuronal integrity shown by MR spectroscopy.

D. Arnold, Z. Caramanos, S. Kalra, 2003, AJNR. American journal of neuroradiology.

Combined aerobic training and dichloroacetate improve exercise capacity and indices of aerobic metabolism in muscle cytochrome oxidase deficiency

P. Matthews, D. Arnold, T. Taivassalo, 1996, Neurology.

A proton magnetic resonance spectroscopic imaging study

D. Arnold, F. Dubeau, F. Cendes, 2007 .

Function and organization in dysgenic cortex. Case report.

D. Arnold, M. Avoli, J. Villemure, 1997, Journal of neurosurgery.

Proton magnetic resonance spectroscopy for the diagnosis and management of cerebral disorders.

D. Arnold, D L Arnold, T M Rudkin, 1999, Archives of neurology.

Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE

D. Arnold, P. Calabresi, S. Sheikh, 2015, Multiple sclerosis.

Recovery of N‐acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy

D. Arnold, N. Cashman, A. Genge, 1998, Neuroreport.

Characterization of astrocytomas, meningiomas, and pituitary adenomas by phosphorus magnetic resonance spectroscopy.

E. Shoubridge, D. Arnold, J. Villemure, 1991, Journal of neurosurgery.

Proton Magnetic Resonance Spectroscopic Imaging Can Predict Length of Survival in Patients with Supratentorial Gliomas

D. Arnold, A. Sadikot, J. Villemure, 2003, Neurosurgery.

Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis.

P M Matthews, P. Matthews, M. Jenkinson, 2000, Brain : a journal of neurology.

Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: Assessment of the load of disease

P M Matthews, P. Matthews, D. Arnold, 1990, Magnetic resonance in medicine.

Magnetic resonance imaging as a surrogate for treatment effect on multiple sclerosis relapses

D. Arnold, D. Goodin, 2009, Annals of neurology.

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial

Jeffrey A. Cohen, D. Arnold, X. Montalban, 2019, The Lancet Neurology.

Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies.

D. Arnold, H. Atkins, G. Kraft, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis

D. Arnold, H. Atkins, M. Freedman, 2006, Neurology.

Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease

P. Matthews, D. Arnold, F. Andermann, 1993, Neurology.

Alemtuzumab CARE-MS I 5-year follow-up

Jeffrey A. Cohen, D. Arnold, H. Hartung, 2017, Neurology.

Incidence and Timing of Thyroid Adverse Events in Patients with RRMS Treated with Alemtuzumab through 5 Years of the CARE-MS Studies (P2.086)

Jeffrey A. Cohen, D. Arnold, L. Kasten, 2016 .

ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis

D. Arnold, J. Rochon, M. Freedman, 2017, Multiple sclerosis.

Phase III dose‐comparison study of glatiramer acetate for multiple sclerosis

Jeffrey A. Cohen, D. Arnold, M. Filippi, 2011, Annals of neurology.

Evaluation of automated techniques for the quantification of grey matter atrophy in patients with multiple sclerosis

D. Louis Collins, Douglas L. Arnold, Zografos Caramanos, 2010, NeuroImage.

Dual‐temporal resolution dynamic contrast‐enhanced MRI protocol for blood–brain barrier permeability measurement in enhancing multiple sclerosis lesions

D. Arnold, G. Pike, I. Jelescu, 2011, Journal of magnetic resonance imaging : JMRI.

Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis.

D. Arnold, J. Antel, S. Narayanan, 2005, Archives of neurology.

Aerobic conditioning in patients with mitochondrial myopathies: Physiological, biochemical, and genetic effects

E. Shoubridge, S. Dimauro, D. Arnold, 2001, Annals of neurology.

Diffusion tensor imaging and cognitive speed in children with multiple sclerosis

D. Arnold, J. Sled, B. Banwell, 2011, Journal of the Neurological Sciences.

Secondary Progressive Multiple Sclerosis

D. Arnold, H. Lassmann, T. Chitnis, 2021, Neurology.

Incidence and prevalence of MS in children

D. Arnold, A. Bar-Or, B. Banwell, 2018, Neurology.

Mitochondrial disease. Pulmonary function, exercise performance, and blood lactate levels.

P. Matthews, D. Arnold, D. Eidelman, 1995, Chest.

Entorhinal Cortex MRI Assessment in Temporal, Extratemporal, and Idiopathic Generalized Epilepsy

Neda Bernasconi, Andrea Bernasconi, Frederick Andermann, 2003, Epilepsia.

Examination of the energetics of aging skeletal muscle using nuclear magnetic resonance.

D. Arnold, G. Radda, P. Styles, 1984, Gerontology.

Four‐neighborhood clique kernel: A general framework for Bayesian and variational techniques of noise reduction in magnetic resonance images of the brain

Nizar Bouguila, Douglas L. Arnold, Michael Osadebey, 2014, Int. J. Imaging Syst. Technol..

Erratum to: Optimal selection of regularization parameter in total variation method for reducing noise in magnetic resonance images of the brain

Nizar Bouguila, Douglas L. Arnold, Adni, 2014 .

Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ follow-up of DEFINE, CONFIRM, and ENDORSE

D. Arnold, L. Kappos, A. Bar-Or, 2020, Therapeutic advances in neurological disorders.

Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials

David H. Miller, D. Arnold, A. Bar-Or, 2014, Annals of clinical and translational neurology.

Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials

Jeffrey A. Cohen, D. Arnold, L. Kappos, 2021, European journal of neurology.

Tolerability and Safety of Combined Glatiramer Acetate and N-Acetylcysteine in Relapsing-Remitting Multiple Sclerosis

D. Arnold, F. Grand'Maison, H. Schipper, 2015, Clinical neuropharmacology.

Clinically feasible MTR is sensitive to cortical demyelination in MS

Elizabeth Fisher, Douglas L Arnold, Robert J Fox, 2013, Neurology.

Normalization of neuronal metabolic dysfunction after surgery for temporal lobe epilepsy

P M Matthews, F Cendes, F Andermann, 1997, Neurology.

Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trial

D. Arnold, B. Cree, I. Williams, 2018, Therapeutic advances in neurological disorders.

Use of Imaging in Multiple Sclerosis

D. Arnold, F. Barkhof, M. Filippi, 2010 .

MRI Visualization of Multiple Sclerosis

P. Matthews, D. Arnold, A. Cifelli, 2004 .

MRI and Proton MRS in the Evaluation of Multiple Sclerosis

P. Matthews, D. Arnold, N. Stefano, 1997 .

Patterns of white and gray structural abnormality associated with paediatric demyelinating disorders

D. Arnold, B. Banwell, S. Narayanan, 2022, NeuroImage: Clinical.

Evolving role of MRI in optimizing the treatment of multiple sclerosis: Canadian Consensus recommendations

D. Arnold, A. Traboulsee, David K.B. Li, 2015, Multiple sclerosis journal - experimental, translational and clinical.

BG-12 Increases the Proportion of Patients Free of Clinical and Radiologic Disease Activity in Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study (PD5.005)

D. Arnold, L. Kappos, A. Bar-Or, 2012 .

Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial

D. Arnold, P. Calabresi, B. Kieseier, 2017, BMC Neurology.

Gradient distortions in MRI: Characterizing and correcting for their effects on SIENA-generated measures of brain volume change

D. Louis Collins, Vladimir Fonov, Douglas L. Arnold, 2010, NeuroImage.

The relationship between diffuse axonal damage and fatigue in multiple sclerosis.

D. Arnold, M. Tartaglia, S. Narayanan, 2004, Archives of neurology.

Magnetization transfer can predict clinical evolution in patients with multiple sclerosis

Zografos Caramanos, Sridar Narayanan, D. Arnold, 2002, Journal of Neurology.

Deep learning segmentation of orbital fat to calibrate conventional MRI for longitudinal studies

Douglas L. Arnold, Robert A. Brown, Robert Fratila, 2019, NeuroImage.

The Metabolic Epicenter of Supratentorial Gliomas: A 1H-MRSI Study

Zografos Caramanos, Mark C Preul, Douglas L Arnold, 2009, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Surface‐based analysis reveals regions of reduced cortical magnetization transfer ratio in patients with multiple sclerosis: A proposed method for imaging subpial demyelination

Zografos Caramanos, Sridar Narayanan, Mishkin Derakhshan, 2014, Human brain mapping.

Relating neocortical pathology to disability progression in multiple sclerosis using MRI

D. Louis Collins, Paul M. Matthews, Douglas L. Arnold, 2004, NeuroImage.

Effects of Dimethyl Fumarate on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: Pooled Analysis Phase 3 DEFINE and CONFIRM Studies

D. Arnold, L. Kappos, T. Yousry, 2022, Frontiers in Neurology.

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study

David H. Miller, D. Arnold, C. Pozzilli, 2016, Multiple sclerosis.

Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study

D. Arnold, L. Kappos, A. Bar-Or, 2014, Journal of Neurology.

Evidence for neuroprotection and remyelination using imaging techniques

D. Arnold, 2007, Neurology.

Changes observed in multiple sclerosis using magnetic resonance imaging reflect a focal pathology distributed along axonal pathways

D. Arnold, 2005, Journal of Neurology.

Automated Estimation of Brain Volume in Multiple Sclerosis with BICCR

Johan Montagnat, D. Louis Collins, Alan C. Evans, 2001, IPMI.

Multiple Sclerosis Lesions Segmentation using Spectral Gradient and Graph Cuts

Christian Barillot, Douglas L. Arnold, Jean-Christophe Ferré, 2008 .

T2 Relaxometry Can Lateralize Mesial Temporal Lobe Epilepsy in Patients with Normal MRI

Neda Bernasconi, François Dubeau, Andrea Bernasconi, 2000, NeuroImage.

IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event

D. Arnold, J. Selhorst, R. Kinkel, 2006, Neurology.

Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis

D. Arnold, F. Barkhof, L. Kappos, 2019, Brain : a journal of neurology.

In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis.

P M Matthews, G S Francis, P. Matthews, 1999, Brain : a journal of neurology.

Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results

D. Arnold, L. Kappos, A. Bar-Or, 2021, Multiple sclerosis.

Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

D. Arnold, D. Reich, M. Valis, 2021, The Lancet Neurology.

Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study

D. Arnold, A. Bar-Or, B. Banwell, 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

MRI and Clinical Outcomes of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, in Relapsing Multiple Sclerosis Over 2.5 Years of the Open-Label Extension to a Phase 2 Trial

D. Arnold, X. Montalban, P. Vermersch, 2023, Multiple Sclerosis and Related Disorders.

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials

D. Arnold, L. Kappos, J. Wolinsky, 2020, JAMA neurology.

Short‐term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders

P. M. Matthews, G. Karpati, P. Matthews, 1995, Neurology.

Fatigue in multiple sclerosis: association with disease-related, behavioural and psychosocial factors

D. Arnold, A. Bar-Or, Z. Caramanos, 2007, Multiple sclerosis.

Magnetic Resonance Spectroscopy in Epilepsy: Clinical Issues

D. Arnold, F. Cendes, E. Novotny, 2002 .

Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases

D. Arnold, T. Wyss-Coray, B. Trapp, 2006, Journal of Neuroimmunology.

Interpreting therapeutic effect in multiple sclerosis via MRI contrast enhancing lesions: now you see them, now you don’t

G. B. Pike, D. Arnold, S. Narayanan, 2014, Journal of Neurology.

Proton magnetic resonance spectroscopy in brain white matter disorders

D. Arnold, A. Federico, N. Stefano, 1997, The Italian Journal of Neurological Sciences.

Magnetic resonance spectroscopy in Niemann-Pick disease type C: correlation with diagnosis and clinical response to cholestyramine and lovastatin.

C R Scriver, D. Arnold, M. Shevell, 1994, Pediatric neurology.

Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis

D. Arnold, S. Shang, M. Meergans, 2018, Therapeutic advances in neurological disorders.

Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study

D. Arnold, C. Castrillo‐Viguera, X. You, 2017, Journal of Neurology.

Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis

D. Arnold, B. Kieseier, S. Newsome, 2016, Multiple sclerosis journal - experimental, translational and clinical.

Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis

Peter A Calabresi, Douglas L Arnold, D. Arnold, 2014, BMC Neurology.

Modeling in vivo recovery of intracellular pH in muscle to provide a novel index of proton handling: Application to the diagnosis of mitochondrial myopathy

D. Arnold, T. Taivassalo, D L Arnold, 2001, Magnetic resonance in medicine.

Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial

D. Arnold, X. Montalban, L. Kappos, 2020, The Lancet Neurology.

Proton magnetic resonance spectroscopic imaging for discrimination of absence and complex partial seizures

D. Arnold, F. Cendes, F. Dubeau, 1997, Annals of neurology.

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial

Jeffrey A. Cohen, D. Arnold, X. Montalban, 2019, The Lancet Neurology.

Automatic Detection of Gadolinium-Enhancing Multiple Sclerosis Lesions in Brain MRI Using Conditional Random Fields

D. Louis Collins, Mohak Shah, Tal Arbel, 2012, IEEE Transactions on Medical Imaging.

Improved Precision in the Measurement of Longitudinal Global and Regional Volumetric Changes via a Novel MRI Gradient Distortion Characterization and Correction Technique

D. Louis Collins, Andrew L. Janke, Vladimir Fonov, 2010, MIAR.

Differential Diagnosis of Human Intracranial Tumors in Vivo Using 1H Mr Spectroscopic Imaging and Feature Space for Spectral Pattern Recognition

D. Collins, D. Arnold, M. Preul, 1994 .

Abnormalities in normal-appearing white matter from which multiple sclerosis lesions arise

D. Arnold, P. MomayyezSiahkal, E. Fisher, 2021, Brain communications.

The relation of focal white matter signal abnormality and focal volume loss in multiple sclerosis

D. Arnold, D. L. Collins, I. Kezele, 2007, Multiple sclerosis.

Local magnetization transfer ratio signal inhomogeneity is related to subsequent change in MTR in lesions and normal-appearing white-matter of multiple sclerosis patients

D. Louis Collins, Douglas L. Arnold, H. L. Atkins, 2005, NeuroImage.

The role of edema and demyelination in chronic T1 black holes: A quantitative magnetization transfer study

Sridar Narayanan, Ives Levesque, Douglas L Arnold, 2005, Journal of magnetic resonance imaging : JMRI.

Evolution of focal and diffuse magnetisation transfer abnormalities in multiple sclerosis

D. Arnold, C. Laule, I. Vavasour, 2003, Journal of Neurology.

Axonal metabolic recovery in multiple sclerosis patients treated with interferon β–1b

Zografos Caramanos, Sridar Narayanan, Daniel Pelletier, 2001, Journal of Neurology.

Patterning Chronic Active Demyelination in Slowly Expanding/Evolving White Matter MS Lesions

D. Arnold, E. Fisher, C. Elliott, 2020, American Journal of Neuroradiology.

Defining multiple sclerosis subtypes using machine learning

D. Arnold, O. Ciccarelli, A. Thompson, 2019 .

white matter lesion load in patients with secondary progressive multiple sclerosis

D. Arnold, Z. Caramanos, S. Narayanan, 2009 .

Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis.

Jeffrey A. Cohen, D. Arnold, H. Wiendl, 2023, Multiple sclerosis and related disorders.

Automated detection of focal cortical dysplasia lesions using computational models of their MRI characteristics and texture analysis

D. Louis Collins, Neda Bernasconi, Robert E. Kearney, 2003, NeuroImage.

Imaging axonal damage of normal-appearing white matter in multiple sclerosis.

P M Matthews, G S Francis, P. Matthews, 1998, Brain : a journal of neurology.

Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques

P M Matthews, G S Francis, P. Matthews, 1992, Annals of neurology.

Neuronal dysfunction in children with newly diagnosed temporal lobe epilepsy.

D. Arnold, F. Cendes, F. Andermann, 2000, Pediatric neurology.

Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study

D. Arnold, F. Then Bergh, A. Wundes, 2022, Advances in Therapy.

In vivo muscle magnetic resonance spectroscopy in the clinical investigation of mitochondria1 disease

P. Matthews, E. Shoubridge, D. Arnold, 1991, Neurology.

Voxel-based analysis of the evolution of magnetization transfer ratio to quantify remyelination and demyelination with histopathological validation in a multiple sclerosis lesion

D. Louis Collins, Douglas L. Arnold, H. L. Atkins, 2007, NeuroImage.

Functional Magnetic Resonance Imaging and Multiple Sclerosis: Cortical Reorganisation and Recovery

P. Matthews, D. Arnold, H. Reddy, 2001 .

Axonal Damage in Multiple Sclerosis Patients with High versus Low Expanded Disability Status Scale Score

Sridar Narayanan, Louis Collins, Jack P Antel, 2004, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Axonal Injury and Disability in Multiple Sclerosis: Magnetic Resonance Spectroscopy as a Measure of Dynamic Pathological Change in White Matter

P. Matthews, D. Arnold, S. Narayanan, 2001 .

Putting Magnetic Resonance Spectroscopy Studies in Context: Axonal Damage and Disability in Multiple Sclerosis

P. Matthews, D. Arnold, J. Wolinsky, 1998, Seminars in neurology.

Brain volume and fatigue in patients with postpoliomyelitis syndrome.

D. Arnold, Z. Caramanos, S. Narayanan, 2014, PM & R : the journal of injury, function, and rehabilitation.

Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial

Jeffrey A. Cohen, D. Arnold, A. Bar-Or, 2016, The Lancet Neurology.

Segmentation of magnetization transfer ratio lesions for longitudinal analysis of demyelination and remyelination in multiple sclerosis

Douglas L. Arnold, Sridar Narayanan, Robert A. Brown, 2013, NeuroImage.

MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study.

D. Arnold, A. Bar-Or, B. Banwell, 2018, The Lancet. Child & adolescent health.

Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study

Daniela Pohl, Amit Bar-Or, Guillaume Sebire, 2011, The Lancet Neurology.

Magnetic resonance spectroscopy and imaging of the thalamus in idiopathic generalized epilepsy.

F Andermann, D. Arnold, F. Andermann, 2003, Brain : a journal of neurology.

Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis

D. Arnold, A. Bar-Or, B. Weinstock-Guttman, 2020, JAMA neurology.

Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis I (CARE-MS I): A Phase 3 Study in Relapsing-Remitting Treatment-Naïve Patients (S01.006)

Jeffrey A. Cohen, D. Arnold, H. Weiner, 2012 .

Mental fatigue alters the pattern and increases the volume of cerebral activation required for a motor task in multiple sclerosis patients with fatigue

D. Arnold, M. Tartaglia, S. Narayanan, 2008, European journal of neurology.

N‐acetylaspartate: Usefulness as an indicator of viable neuronal tissue

P M Matthews, B D Trapp, D. Arnold, 2001, Annals of neurology.

Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM

D. Arnold, L. Kappos, A. Bar-Or, 2016, Multiple sclerosis journal - experimental, translational and clinical.

Trial of Fingolimod versus Interferon Beta‐1a in Pediatric Multiple Sclerosis

D. Arnold, A. Bar-Or, E. Waubant, 2018, The New England journal of medicine.

Ozanimod Demonstrates Efficacy and Safety in a Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Phase 3 Trial of Relapsing Multiple Sclerosis (SUNBEAM) (P3.396)

Jeffrey A. Cohen, D. Arnold, X. Montalban, 2018 .

Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis

A. Camm, D. Arnold, L. Kappos, 2017, Multiple sclerosis.

Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial

J. Camm, D. Arnold, L. Kappos, 2016, The Lancet Neurology.

Propagating Uncertainty Across Cascaded Medical Imaging Tasks for Improved Deep Learning Inference

Raghav Mehta, Tal Arbel, Douglas L. Arnold, 2019, IEEE Transactions on Medical Imaging.

Personalized Prediction of Future Lesion Activity and Treatment Effect in Multiple Sclerosis from Baseline MRI

Jean-Pierre R. Falet, T. Arbel, D. Arnold, 2022, MIDL.

Contribution of the cerebellum to cognitive performance in children and adolescents with multiple sclerosis

Vladimir Fonov, Katrin Weier, Douglas L Arnold, 2016, Multiple sclerosis.

White matter changes in paediatric multiple sclerosis and monophasic demyelinating disorders

Massimo Filippi, Douglas L. Arnold, Amit Bar-Or, 2017, Brain : a journal of neurology.

1H NMR characterization of normal human cerebrospinal fluid and the detection of methylmalonic acid in a vitamin B12 deficient patient

E. Shoubridge, D. Arnold, B. Sanctuary, 1991, NMR in biomedicine.

Magnetic Resonance Spectroscopy in Multiple Sclerosis

D. Arnold, M. Filippi, G. Comi, 2001, Topics in Neuroscience.

Magnetic resonance imaging of multiple sclerosis: new insights linking pathology to clinical evolution

P M Matthews, P. Matthews, D. Arnold, 2001, Current opinion in neurology.

Imaging axonal damage in multiple sclerosis by means of MR spectroscopy

Shrikanth S. Narayanan, D. Arnold, A. Federico, 2000, Neurological Sciences.

P 2 Effect of ocrelizumab on humoral immunity markers in the phase iii, double-blind, double-dummy, IFN β -1a–controlled OPERA I and OPERA II studies

G. Comi, D. Arnold, L. Kappos, 2017, Clinical Neurophysiology.

1H-MRS quantification of tNA and tCr in patients with multiple sclerosis: a meta-analytic review.

Zografos Caramanos, Sridar Narayanan, Douglas L Arnold, 2005, Brain : a journal of neurology.

Guidelines for using proton MR spectroscopy in multicenter clinical MS studies

P M Matthews, M Filippi, P. Matthews, 2007, Neurology.

Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study

D. Arnold, M. Freedman, J. Wolinsky, 2019, Multiple sclerosis.

Factors associated with health care utilization in pediatric multiple sclerosis.

D. Arnold, A. Bar-Or, B. Banwell, 2019, Multiple sclerosis and related disorders.

Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials

D. Arnold, M. Sormani, A. Bar-Or, 2013, Neurology.

Regional brain atrophy in children with multiple sclerosis

D. Louis Collins, Vladimir Fonov, Douglas L. Arnold, 2011, NeuroImage.

Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials

D. Arnold, L. Kappos, A. Cross, 2022, Frontiers in Immunology.

CNN Detection of New and Enlarging Multiple Sclerosis Lesions from Longitudinal Mri Using Subtraction Images

Tal Arbel, Douglas L. Arnold, Nazanin Mohammadi Sepahvand, 2020, 2020 IEEE 17th International Symposium on Biomedical Imaging (ISBI).

Magnetization transfer saturation reveals subclinical optic nerve injury in pediatric-onset multiple sclerosis

D. Arnold, A. Bar-Or, J. Sled, 2022, Multiple sclerosis.

Single-timepoint low-dimensional characterization and classification of acute versus chronic multiple sclerosis lesions using machine learning

N. Paragios, D. Arnold, E. Fisher, 2022, NeuroImage.

Comparison of Spinal Cord Magnetic Resonance Imaging Features Among Children With Acquired Demyelinating Syndromes

D. Arnold, A. Bar-Or, B. Banwell, 2021, JAMA Network Open.

Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis

D. Arnold, A. Bar-Or, B. Banwell, 2021, Multiple sclerosis.

Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation

Thomas E. Nichols, D. Arnold, H. Ganjgahi, 2021, Multiple sclerosis.

High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS

D. Arnold, A. Bar-Or, M. Freedman, 2019, Neurology: Neuroimmunology & Neuroinflammation.

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

D. Arnold, L. Kappos, S. Greenberg, 2015, The New England journal of medicine.

Adaptive Voxel, Texture and Temporal Conditional Random Fields for Detection of Gad-Enhancing Multiple Sclerosis Lesions in Brain MRI

D. Louis Collins, Hassan Rivaz, Tal Arbel, 2013, MICCAI.

Temporal Hierarchical Adaptive Texture CRF for Automatic Detection of Gadolinium-Enhancing Multiple Sclerosis Lesions in Brain MRI

D. Louis Collins, Hassan Rivaz, Tal Arbel, 2015, IEEE Transactions on Medical Imaging.

Multiple Sclerosis lesion segmentation using an automated multimodal Graph Cut

D. Louis Collins, Christian Barillot, Jérémy Lecoeur, 2016 .

Alemtuzumab Decreased MRI Disease Activity Through 6 Years in Patients With Highly Active RRMS and an Inadequate Response to Prior Therapy: CARE-MS II Extension Study (S12.006)

D. Arnold, À. Rovira, A. Traboulsee, 2017 .

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS

Jeffrey A. Cohen, D. Arnold, H. Weiner, 2016, Neurology.

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study

Jeffrey A. Cohen, D. Arnold, D. Snydman, 2018, Multiple sclerosis.

Proton Magnetic Resonance Spectroscopic Imaging Studies in Patients with Newly Diagnosed Partial Epilepsy

F Andermann, D. Arnold, F. Dubeau, 2000, Epilepsia.

Proton Magnetic Resonance Spectroscopic Imaging in Patients with Extratemporal Epilepsy

D. Arnold, F. Cendes, F. Dubeau, 1998, Epilepsia.

Axonal injury in the cerebral normal-appearing white matter of patients with multiple sclerosis is related to concurrent demyelination in lesions but not to concurrent demyelination in normal-appearing white matter

Douglas L. Arnold, G. Bruce Pike, John G. Sled, 2006, NeuroImage.

Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial

D. Arnold, L. Kappos, S. S. Geertsen, 2023, Multiple sclerosis.

Multiple sclerosis (PP-038)

D. Arnold, F. Najafi, A. Bar-Or, 2010 .

Rotation-invariant multi-contrast non-local means for MS lesion segmentation

D. Louis Collins, Pierrick Coupé, Nicolas Guizard, 2015, NeuroImage: Clinical.

Probabilistic Multiple Sclerosis Lesion Classification Based on Modeling Regional Intensity Variability and Local Neighborhood Information

D. Louis Collins, Tal Arbel, Douglas L. Arnold, 2015, IEEE Transactions on Biomedical Engineering.

Intracellular phosphates in inclusion body myositis—A 31P magnetic resonance spectroscopy study

D. Arnold, T. Taivassalo, A. Genge, 1998 .

Trimmed-Likelihood Estimation for Focal Lesions and Tissue Segmentation in Multisequence MRI for Multiple Sclerosis

D. Louis Collins, Christian Barillot, Douglas L. Arnold, 2011, IEEE Transactions on Medical Imaging.

Effect of dimethyl fumarate on lymphocytes in RRMS

D. Arnold, L. Kappos, A. Bar-Or, 2019, Neurology.

Lesion distribution in children with clinically isolated syndromes

Amit Bar-Or, Sridar Narayanan, Douglas L Arnold, 2008, Annals of neurology.

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis

D. Arnold, P. Sørensen, F. Zipp, 2014, Journal of Neurology.

Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI

D. Arnold, A. Bar-Or, V. Fonov, 2018, Multiple sclerosis.

A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis.

D. Arnold, J. Oger, M. Freedman, 2004, Clinical therapeutics.

Statistics for Investigation of Multimodal MR Imaging Data and an Application to Multiple Sclerosis Patients

D. L. Collins, D. Arnold, C. Wolfson, 1996, NMR in biomedicine.

Proton Magnetic Resonance Spectroscopic Imaging and Magnetic Resonance Imaging Volumetry in the Lateralization of Temporal Lobe Epilepsy : A Series of 100 Patiekts

D. Arnold, F. Dubeau, F. Cendes, 2004 .

Clinical Research Relation of Interictal Spike Frequency to H-MRSI-Measured NAA/Cr

J. Gotman, D. Arnold, Z. Caramanos, 1999 .

In vivo differentiation of astrocytic brain tumors and isolated demyelinating lesions of the type seen in multiple sclerosis using 1H magnetic resonance spectroscopic imaging

D. Arnold, Z. Caramanos, M. Preul, 1998, Annals of neurology.

Axonal dysfunction and disability in a relapse of multiple sclerosis: Longitudinal study of a patient

P M Matthews, G S Francis, P. Matthews, 1997, Neurology.

Combining SIENA and SIENAx for improved quantification of grey and white matter atrophy

D. Arnold, D. L. Collins, S. Narayanan, 2011 .

Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis

D. Arnold, E. Fisher, C. Elliott, 2023, Multiple sclerosis.

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis

Jeffrey A. Cohen, Deborah M. Miller, D. Arnold, 2020 .

Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS

Alexander Parajeles Vindas, P. Kowey, D. Arnold, 2016, Neurology. Clinical practice.

White matter integrity and math performance in pediatric multiple sclerosis: a diffusion tensor imaging study

Sridar Narayanan, John G Sled, Brenda L Banwell, 2011, Neuroreport.

Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis

P. Matthews, D. Arnold, A. Blamire, 2003, Journal of Neurology.

Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial

Michael Wall, D. Barlett, J. Herbert, 2002, Multiple sclerosis.

The lesions of multiple sclerosis.

D. Arnold, D. Paty, 2002, The New England journal of medicine.

Magnetization Transfer Ratio Imaging Is Feasible in Large Multicenter MS Trials

Sridar Narayanan, Mishkin Derakhshan, Katherine Dawson, 2010 .

Measuring demyelination and remyelination in acute multiple sclerosis lesion voxels.

Sridar Narayanan, Ives R Levesque, Douglas L Arnold, 2009, Archives of neurology.

Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis

D. Arnold, H. Atkins, M. Freedman, 2017, Multiple sclerosis.

Disrupted cognitive development following pediatric acquired demyelinating syndromes: a longitudinal study

D. Arnold, A. Bar-Or, B. Banwell, 2021, Child neuropsychology : a journal on normal and abnormal development in childhood and adolescence.

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the DEFINE study

D. Arnold, L. Kappos, A. Bar-Or, 2013, Journal of Neurology.

Reproducibility of quantitative magnetization‐transfer imaging parameters from repeated measurements

Sridar Narayanan, Ives R Levesque, Douglas L Arnold, 2010, Magnetic resonance in medicine.

Image Quality Evaluation in Clinical Research: A Case Study on Brain and Cardiac MRI Images in Multi-Center Clinical Trials

Marius Pedersen, Katrina Wendel-Mitoraj, Michael Osadebey, 2018, IEEE Journal of Translational Engineering in Health and Medicine.

Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis?

P M Matthews, M Filippi, P. Matthews, 1999, Brain : a journal of neurology.

Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination

D. Arnold, L. Kappos, S. Cohan, 2021, Therapeutic advances in neurological disorders.

Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much?

D. Arnold, A. Bar-Or, J. Antel, 2009, Archives of neurology.

The place of MRI in monitoring the individual MS patient

D. Arnold, 2007, Journal of the Neurological Sciences.

Increased mental health care use by mothers of children with multiple sclerosis

D. Arnold, A. Bar-Or, B. Banwell, 2020, Neurology.

Effect of BG-12 in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study (P01.130)

D. Arnold, L. Kappos, A. Bar-Or, 2012 .

Non-Local Means Inpainting of MS Lesions in Longitudinal Image Processing

D. Louis Collins, Pierrick Coupé, Nicolas Guizard, 2015, Front. Neurosci..

Alemtuzumab improves visual outcomes in treatment-naïve patients with relapsing–/INS;remitting multiple sclerosis (RRMS): Analysis from the phase 3 CARE-MS I study

D. Arnold, H. Hartung, E. Havrdová, 2013, Journal of the Neurological Sciences.

Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study)

D. Arnold, C. Pozzilli, H. Hartung, 2019 .

Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo groupy

Jeffrey A. Cohen, S. Cole, D. Arnold, 2002, Multiple sclerosis.

Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis

D. Arnold, H. Atkins, M. Freedman, 2018, Multiple sclerosis.

Magnetic resonance spectroscopy: imaging axonal damage in MS

D. Arnold, 1999, Journal of Neuroimmunology.

Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study)

D. Arnold, C. Pozzilli, H. Hartung, 2019 .

Neuroimaging in amyotrophic lateral sclerosis

D. Arnold, S. Kalra, 2003, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

STRATEGIES FOR MONITORING AND ASSESSING THERAPY

D. Arnold, 2006 .

RRMS Patients Switching from SC IFNB-1a to Alemtuzumab in the CARE-MS I and II Extension Study Have a Reduced Rate of Brain Volume Loss (P6.183)

Jeffrey A. Cohen, D. Arnold, F. Barkhof, 2016 .

Estimating treatment effect for individuals with progressive multiple sclerosis using deep learning

Doina Precup, T. Arbel, D. Arnold, 2021, medRxiv.

Surface-based techniques reveal regions of reduced cortical magnetization transfer ratio in patients with MS

D. Collins, D. Arnold, Z. Caramanos, 2009 .

Assessing the differential sensitivities of wave-CAIPI ViSTa myelin water fraction and magnetization transfer saturation for efficiently quantifying tissue damage in MS.

D. Arnold, D. Rudko, S. Narayanan, 2021, Multiple sclerosis and related disorders.

Prospective characterization of children positive for anti-MOG antibodies meeting Multiple Sclerosis diagnostic criteria

D. Arnold, A. Bar-Or, B. Banwell, 2019 .

Daclizumab HYP Versus Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis: Primary Results of the DECIDE Study (S4.003)

D. Arnold, L. Kappos, S. Greenberg, 2015 .

Baseline Demographics and Disease Characteristics from ORATORIO, a Phase III Trial Evaluating Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis (P7.017)

D. Arnold, X. Montalban, A. Bar-Or, 2015 .

Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: The DEFINE study

D. Arnold, L. Kappos, A. Bar-Or, 2014, Multiple sclerosis.

Neuroprotection with glatiramer acetate: evidence from the PreCISe trial

D. Arnold, S. Antel, S. Narayanan, 2013, Journal of Neurology.

Regional variations in normal brain shown by quantitative magnetization transfer imaging

I Levesque, G B Pike, D. Arnold, 2004, Magnetic resonance in medicine.

Immunogenicity of Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients in the CARE-MS II Study (P07.101)

Jeffrey A. Cohen, D. Arnold, H. Weiner, 2013 .

1H-MRSI evidence for cortical gray matter pathology that is independent of cerebral white matter lesion load in patients with secondary progressive multiple sclerosis

D. Arnold, Z. Caramanos, S. Narayanan, 2009, Journal of the Neurological Sciences.

Rapid improvement in cortical neuronal integrity in amyotrophic lateral sclerosis detected by proton magnetic resonance spectroscopic imaging

Douglas L. Arnold, Sanjay Kalra, Angela Genge, 2006, Journal of Neurology.

Improving Pathological Structure Segmentation via Transfer Learning Across Diseases

Raghav Mehta, Doina Precup, Tal Arbel, 2019, DART/MIL3ID@MICCAI.

Segmentation-Consistent Probabilistic Lesion Counting

T. Arbel, D. Arnold, J. Schroeter, 2022, MIDL.

Magnetic Resonance Spectroscopy Guided Brain Tumor Resection: Differentiation Between Recurrent Glioma and Radiation Change in Two Diagnostically Difficult Cases

R Kasrai, D. Arnold, Z. Caramanos, 1998, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

N-acetylaspartate: A marker of neuronal integrity. Authors' reply

D. Arnold, A. Pfefferbaum, E. Adalsteinsson, 2001 .

Interferon β-1b and glatiramer acetate effects on permanent black hole evolution

G. Comi, D. Arnold, D. Goodin, 2011, Neurology.

Trial Designs Likely to Meet Valid Long-Term Alzheimer's Disease Progression Effects: Learning from the Past, Preparing for the Future

D. Arnold, D. Streiner, A. Kemp, 2009, International journal of Alzheimer's disease.

Surgical outcome in patients with epilepsy and dual pathology.

D. Arnold, W. Harkness, S. Shorvon, 1999, Brain : a journal of neurology.

Frequency and characteristics of dual pathology in patients with lesional epilepsy

F Cendes, D R Fish, F Andermann, 1995, Neurology.

A prospective, randomized, placebo‐controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: feasibility and results

D. Arnold, S. Kalra, A. Genge, 2003, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

Magnetic resonance spectroscopy for monitoring neuronal integrity in amyotrophic lateral sclerosis.

D. Arnold, S. Kalra, 2006, Advances in experimental medicine and biology.

Primary Analysis of a Randomized Phase II Study to Evaluate the Efficacy and Safety of Evobrutinib, a BTK Inhibitor, in Patients with Relapsing MS

D. Arnold, X. Montalban, J. Wolinsky, 2019 .

Clinical Efficacy of BG-12 (Dimethyl Fumarate) in Relapsing-Remitting Multiple Sclerosis (RRMS): An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies (P07.097)

D. Arnold, R. Gold, K. Selmaj, 2013 .

Using pattern analysis of in vivo proton MRSI data to improve the diagnosis and surgical management of patients with brain tumors

D. Arnold, J. Villemure, Z. Caramanos, 1998, NMR in biomedicine.

Investigation of human mitochondrial myopathies by phosphorus magnetic resonance spectroscopy

D. Arnold, G. Radda, D. Taylor, 1985, Annals of neurology.

Elevated serum inflammatory markers in post-poliomyelitis syndrome

D. Arnold, A. Bar-Or, J. Collet, 2008, Journal of the Neurological Sciences.

Automated quality control of brain MR images

Douglas L Arnold, Elias L Gedamu, D L Collins, 2008, Journal of magnetic resonance imaging : JMRI.

Myoclonus epilepsy and ragged-red fibres (MERRF). 1. A clinical, pathological, biochemical, magnetic resonance spectrographic and positron emission tomographic study.

E. Shoubridge, D. Arnold, F. Andermann, 1989, Brain : a journal of neurology.

Optimal selection of regularization parameter in total variation method for reducing noise in magnetic resonance images of the brain

D. Arnold, N. Bouguila, the Adni, 2014 .

The clique potential of Markov random field in a random experiment for estimation of noise levels in 2D brain MRI

Nizar Bouguila, Douglas L. Arnold, Michael Osadebey, 2013, Int. J. Imaging Syst. Technol..

Multivariate Statistics for Detection of MS Activity in Serial Multimodal MR Images

D. Louis Collins, Douglas L. Arnold, Sylvain Prima, 2003, MICCAI.

Bayesian Classification of Multiple Sclerosis Lesions in Longitudinal MRI Using Subtraction Images

D. Louis Collins, Tal Arbel, Douglas L. Arnold, 2010, MICCAI.

Clinical Efficacy and Safety of Peginterferon beta-1a in Relapsing Multiple Sclerosis: Data from the Pivotal Phase 3 ADVANCE Study (S31.006)

D. Arnold, P. Calabresi, L. Balcer, 2013 .

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.

D. Arnold, F. Zipp, E. Havrdová, 2014, Journal of neurology.

Induction of Antigen-Specific Tolerance in Multiple Sclerosis After Immunization With DNA Encoding Myelin Basic Protein in a Randomized, Placebo-Controlled Phase 1/2 Trial

D. Arnold, L. Weiner, A. Bar-Or, 2007 .

A Validation Study of Multicenter Diffusion Tensor Imaging: Reliability of Fractional Anisotropy and Diffusivity Values

J. Debbins, D. Arnold, M. Lowe, 2012, American Journal of Neuroradiology.

Is It Possible to Differentiate the Impact of Pediatric Monophasic Demyelinating Disorders and Multiple Sclerosis After a First Episode of Demyelination?

D. Louis Collins, Vladimir Fonov, Douglas L. Arnold, 2014, STIA.

Interim Analysis of 2-year Clinical Efficacy and Safety of Peginterferon Beta-1a in Patients with Relapsing-Remitting Multiple Sclerosis: Data from the Pivotal Phase 3 ADVANCE Study (S4.005)

D. Arnold, S. Sheikh, B. Kieseier, 2014 .

Relapse Outcomes with Alemtuzumab vs IFNB-1a in Active Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P07.098)

D. Arnold, X. Montalban, H. Weiner, 2013 .

Secondary Progressive Multiple Sclerosis

D. Arnold, T. Chitnis, R. Fox, 2021, Neurology.

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

D. Arnold, L. Kappos, S. Greenberg, 2015, The New England journal of medicine.

Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases

D. Arnold, T. Wyss-Coray, B. Trapp, 2006, Journal of Neuroimmunology.

ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis

D. Arnold, J. Rochon, M. Freedman, 2017, Multiple sclerosis.

Quantitative magnetization transfer imaging made easy with qMTLab: Software for data simulation, analysis, and visualization

Julien Cohen-Adad, G. Bruce Pike, John G. Sled, 2015 .

Towards a better understanding of pseudoatrophy in the brain of multiple sclerosis patients

D. Arnold, N. de Stefano, 2015, Multiple sclerosis.

Diminished Th 17 ( not Th 1 ) responses underlie MS disease abrogation after HSCT

D. Arnold, H. Atkins, M. Duddy, 2012 .

2010 McDonald criteria for diagnosing pediatric multiple sclerosis

D. Arnold, A. Bar-Or, J. Sled, 2012, Annals of neurology.

Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis

D. Arnold, L. Kappos, R. Gold, 2015, European journal of neurology.

Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.

D. Arnold, X. Montalban, J. Wolinsky, 2019, The New England journal of medicine.

Diffusely abnormal white matter converts to T2 lesion volume in the absence of acute inflammation

D. Collins, D. Arnold, M. Dadar, 2021, bioRxiv.

EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis

D. Arnold, F. Barkhof, M. Filippi, 2006, European journal of neurology.

Magnetization transfer ratio is unable to lateralize epileptic foci in patients with temporal lobe epilepsy.

D. Arnold, F. Dubeau, F. Andermann, 2000, AJNR. American journal of neuroradiology.

Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study

D. Arnold, A. Bar-Or, B. Banwell, 2011, The Lancet Neurology.

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis

D. Arnold, A. Bar-Or, M. Freedman, 2008, Multiple sclerosis.

Bayesian MS Lesion Classification Modeling Regional and Local Spatial Information

D. Louis Collins, Tal Arbel, Douglas L. Arnold, 2006, 18th International Conference on Pattern Recognition (ICPR'06).

Trimmed-Likelihood Estimation for Focal Lesions and Tissue Segmentation in Multisequence MRI for Multiple Sclerosis

D. Arnold, C. Barillot, D. García-Lorenzo, 2011, IEEE Transactions on Medical Imaging.

Localization and Registration Issues Important for Serial MRS Studies of Focal Brain Lesions

P. Matthews, D. Arnold, 2007 .

Single-timepoint low-dimensional characterization and classification of acute versus chronic multiple sclerosis lesions using machine learning

N. Paragios, D. Arnold, E. Fisher, 2022, NeuroImage.

Proton Magnetic Resonance Spectroscopy

D. Arnold, Z. Caramanos, D. Pelletier, 2002 .

Blind blur assessment of MRI images using parallel multiscale difference of Gaussian filters

Marius Pedersen, Michael E Osadebey, Douglas L Arnold, 2018, BioMedical Engineering OnLine.

Computational Models of MRI Characteristics of Focal Cortical Dysplasia Improve Lesion Detection

D. Louis Collins, Neda Bernasconi, Robert E. Kearney, 2002, NeuroImage.

Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

D. Arnold, P. Calabresi, L. Balcer, 2014, The Lancet Neurology.